enGene Therapeutics Inc. (ENGN)

NCM – Real Time Price. Currency in USD

1.44

-0.05 (-3.36%)

At close: May 12, 2026, 4:00 PM EDT

1.46

+0.02 (1.39%)

Pre-market: May 13, 2026, 6:08 AM EDT

09.05.2026

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

08.05.2026

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

07.05.2026

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.

07.05.2026

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary d.

07.04.2026

enGene Announces Name Change to enGene Therapeutics Inc.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's on.

12.03.2026

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollment exceeding targets. ENGN plans a pivotal LEGEND cohort update at a spring 2026 medical conference, with a BLA submission for FDA approval anticipated in the second half of 2026.

10.03.2026

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videos

No Data

There is no data to display

Press releases

07.05.2026

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

07.05.2026

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

07.04.2026

enGene Announces Name Change to enGene Therapeutics Inc.

09.03.2026

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update. “As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,” said Ron Cooper, President and Chief Executive Officer, enGe.

enGene Therapeutics Inc. (ENGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videos

No Data

Press releases

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videos

No Data

Press releases

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Search stocks

enGene Therapeutics Inc. (ENGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videos

No Data

Press releases

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videos

No Data

Press releases

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Reports First Quarter 2026 Financial Results and Provides Business Update